Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy (PilotTMS-COG)

July 19, 2017 updated by: University Hospital, Caen

Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study

The purpose of the study is to test a new treatment of social cognition deficits in patients with schizophrenia or schizoaffective disorder by transcranial magnetic stimulation (theta-burst). The study will also identify clinical variables, cognitive and psychomotor most sensitive to treatment, to estimate the most sensitive treatment target, assess tolerance, to assess the impact of repetitive Transcranial Magnetic Stimulation (rTMS) on the brain a multimodal imaging study and compare the imaging variables (resting network, Diffusion Tensor Imaging, magnetic resonance spectroscopic imaging; MRSI) between patients before treatment and healthy subjects.

Study Overview

Detailed Description

The language understanding of other people is based on linguistic decoding mechanisms (phonological, semantic, syntactic ...) but also more on subtle mechanisms for the recognition of emotions and intentions. Interact with another one requires understanding its language but also to infer emotions and intentions. There are patients with schizophrenia suffering from social cognition disorders that impair social interactions; These patients often have difficulty in extracting the non-verbal emotional content of language and have difficulty inferring the thoughts and intentions of others. Recently, we have suggested a link between such deficits and the hypofunction of the medial prefrontal cortex.

Transcranial magnetic stimulation is a noninvasive neuromodulation technique that increases or decreases the focal cortical excitability depending on stimulation parameters. This technique is now commonly used as a therapeutic tool. It has been tried with some success in patients with schizophrenia in some indications:

  • To reduce the auditory verbal hallucinations stimulating the temporal cortex
  • More rarely, to reduce the negative symptoms stimulating the dorsolateral prefrontal cortex So far, the medial prefrontal cortex was not considered as a possible target as the scalp to cortex distance prevent from using conventional stimulation coils. Recently new coils have been developed that permit stimulation of deeper cortical regions.

We hypothesize that the use of transcranial magnetic stimulation with a theta burst intermittent protocol known to increase the cortical excitability and aiming the medial prefrontal cortex with a special antenna will improve social interaction capabilities of schizophrenic patients.

This ambitious and innovative assumption shall be first supported by a study of feasibility which is the subject of this trial.

Moreover, changes in the anatomical and functional connectivity, in brain metabolism and in cortical excitability will be observed after stimulation thanks to a multimodal imaging and the study of P50 wave.

In this pilot study, involving 20 patients, we plan to assess the social cognition deficits before and after 10 sessions of magnetic stimulation (2 sessions per day for 5 consecutive days) using a neuronavigation system and Magstim® stimulator. In order to assess the feasibility and specificity of the stimulation of medial prefrontal cortex (MPC), the effects of this treatment will be compared to the effects of the same treatment aiming the dorsolateral prefrontal cortex (DLPFC), also involved in aspects of negative symptoms of schizophrenia, and placebo effects induced by sham stimulation (using a sham coil). The recording of the P50 wave will be just before and after the 1st session and just after the last stimulation session. An MRI anatomical, functional and spectroscopic be performed before and 30 days after the treatment. A control group of twenty healthy subjects will perform the same MRI acquisitions.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Caen, France, 14033
        • Recruiting
        • CHU de Caen - Centre Esquirol
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • with a diagnosis of schizophrenia or schizoaffective disorder (DSM-IV MINI R)
  • less than 20 years of disease duration
  • Having signed a written informed consent
  • LIS score > 15 or negative PANSS score > 15

Exclusion Criteria:

  • Any change in psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) during the two months preceding the inclusion
  • Pregnant or breastfeeding women
  • Subjects with a neurological condition or with epilepsy
  • Subjects with a counter-indication to MRI or Transcranial stimulation (electronic or metal implants)
  • Subjects that refuse to wear earplugs during MRI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Healthy subjects
Multimodal imaging data acquisitions Clinical data acquisitions
Experimental: TBS-MPC
  • Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia
  • Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Continuous actimetry acquisition
Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Active Comparator: TBS-CPDLF
  • Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia
  • Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Continuous actimetry acquisition
Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Sham Comparator: TBS-Sham
  • Intervention with Sham TBS in 8 patients with schizophrenia
  • Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
  • Continuous actimetry acquisition
Sham stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
V-LIS total score
Time Frame: change from baseline in V-LIS total score compared to 30 days after the end of the treatment
change from baseline in V-LIS total score compared to 30 days after the end of the treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
GLX ratio
Time Frame: change in baseline GLX ratio measured in MRSI compared to 30 days after the end of the treatment
GLX (= Glutamine + Glutamate) ratio are measured in the DLPFC and in the MPC
change in baseline GLX ratio measured in MRSI compared to 30 days after the end of the treatment
P50 wave amplitude
Time Frame: change in baseline P50 amplitude compared to immediately after the end of the treatment
change in baseline P50 amplitude compared to immediately after the end of the treatment
Motor activity
Time Frame: change in baseline motor activity measured with an actimeter compared to 30 days after the end of the treatment
change in baseline motor activity measured with an actimeter compared to 30 days after the end of the treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Clément Nathou, MD, University Hospital, Caen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Anticipated)

December 1, 2017

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

May 4, 2015

First Submitted That Met QC Criteria

May 7, 2015

First Posted (Estimate)

May 12, 2015

Study Record Updates

Last Update Posted (Actual)

July 21, 2017

Last Update Submitted That Met QC Criteria

July 19, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Cognition in Patients With Schizophrenia

Clinical Trials on Active TBS

3
Subscribe